Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malignant gliomas are associated with high mortality due to infiltrative growth, recurrence, and malignant progression. Even with the most efficient therapy combinations, median survival of the glioblastoma multiforme (grade 4) patients is less than 15 months. Therefore, new treatment approaches are urgently needed. We describe here identification of a novel homing peptide that recognizes tumor vessels and invasive tumor satellites in glioblastomas. We demonstrate successful brain tumor imaging using radiolabeled peptide in whole-body SPECT/CT imaging. Peptide-targeted delivery of chemotherapeutics prolonged the lifespan of mice bearing invasive brain tumors and significantly reduced the number of tumor satellites compared with the free drug. Moreover, we identified mammary-derived growth inhibitor (MDGI/H-FABP/FABP3) as the interacting partner for our peptide on brain tumor tissue. MDGI was expressed in human brain tumor specimens in a grade-dependent manner and its expression positively correlated with the histologic grade of the tumor, suggesting MDGI as a novel marker for malignant gliomas.

Original publication

DOI

10.1158/1535-7163.MCT-13-0684

Type

Journal article

Journal

Mol Cancer Ther

Publication Date

04/2014

Volume

13

Pages

996 - 1007

Keywords

Animals, Biomarkers, Tumor, Cell Line, Tumor, Drug Delivery Systems, Fatty Acid-Binding Proteins, Female, Glioblastoma, Humans, Indium, Mice, Mice, Nude, Neoplasm Grading, Neoplasms, Experimental, Organ Specificity, Peptides, Rats, Tomography, Emission-Computed, Single-Photon, Xenograft Model Antitumor Assays